 |
|
|
| |
WEIGHT CHANGES AFTER SWITCH TO
DORAVIRINE/LAMIVUDINE/TDF IN THE DRIVE-SHIFT TRIAL
|
| |
| |
Presented at the Virtual 23rdInternational AIDS Conference; San Francisco & Oakland, California, USA
Reported by Jules Levin
https://go.aws/3gwDBH1
July 06-10, 2020
Princy Kumar1, Margaret Johnson2, Zhi Jin Xu3, Elizabeth Martin3, Peter Sklar3, Wayne Greaves3
1Georgetown University, Washington DC; 2Royal Free Hospital, London. UK; 3Merck & Co., Inc., Kenilworth NJ, USA.
|
| |
|
|
|
|
|
